Search Results - "Rogers, Sherise"

Unraveling Racial Disparities in Supportive Care Medication Use among End-of-Life Pancreatic Cancer Patients: Focus on Pain Management and Psychiatric Therapies by Allen, John M, Awunti, MegCholack, Guo, Yi, Bian, Jiang, Rogers, Sherise C, Scarton, Lisa, DeRemer, David L, Wilkie, Diana J

“…Supportive care medication use differences may contribute to racial disparities observed in health-related quality of life in patients with pancreatic cancer…”
Get full text

Analysis of pancreatic cancer treatment and survival disparities in Florida throughout the Covid-19 pandemic by Telisnor, Guettchina, Lim, Alexander, Zhang, Zhongyue, Lou, XiangYang, Nassour, Ibrahim, Salloum, Ramzi G., Rogers, Sherise C.

“…Pancreatic ductal adenocarcinoma (PDAC) is currently the third-leading cause of cancer-related death in the United States. African Americans (AAs) with PDAC…”
Get full text

Review of genetic and pharmacogenetic differences in cytotoxic and targeted therapies for pancreatic cancer in African Americans by Telisnor, Guettchina, DeRemer, David L., Frimpong, Esther, Agyare, Edward, Allen, John, Ricks-Santi, Luisel, Han, Bo, George, Thomas, Rogers, Sherise C.

“…Pancreatic ductal adenocarcinoma (PDAC) is currently the third leading cause of cancer mortality and the incidence is projected to increase by 2030. Despite…”
Get full text

Safety and efficacy of peptide receptor radionuclide therapy in neuroendocrine tumors: A single center experience by Sukrithan, Vineeth, Armbruster, Heather, Rogers, Sherise, Vogt, Sherry Mori, Grenade, Cassandra, Verschraegen, Claire, Zhou, Ye, Goyal, Ashima, Natwa, Mona, Hussein, Akram, Barr, Hallie, Konate, Dramane, Batdorf, Rochelle, Brown, Andrew, Williams, Bonnie, Zhao, Songzhu, Wei, Lai, Xu, Menglin, Shah, Manisha H, Konda, Bhavana

“…Peptide receptor radionucleotide therapy (PRRT) with 177Lu-dotatate is widely used for the treatment of patients with neuroendocrine tumors (NETs). We analyzed…”
Get full text

Evaluation of Anticancer Activity of Zhubech, a New 5-FU Analog Liposomal Formulation, against Pancreatic Cancer by Ndemazie, Nkafu Bechem, Bulusu, Raviteja, Zhu, Xue You, Frimpong, Esther Kesewaah, Inkoom, Andriana, Okoro, Joy, Ebesoh, Dexter, Rogers, Sherise, Han, Bo, Agyare, Edward

“…Pancreatic cancer is projected to be the second leading cause of cancer-related death by 2030 in the US. The benefits of the most common systemic therapy for…”
Get full text

Discontinuation of Everolimus Due to Related and Unrelated Adverse Events in Cancer Patients: A Meta-Analysis by Rogers, Sherise C., Garcia, Christine A., Wu, Shenhong

“…A meta-analysis of randomized controlled trials (RCTs) was performed to examine the risk of everolimus discontinuation due to related and unrelated adverse…”
Get full text

Florida-California Cancer Research, Education and Engagement (CaRE2) Health Equity Center: Structure, Innovations, and Initial Outcomes by Reams, R. Renee, Odedina, Folakemi T., Carpten, John D., Redda, Kinfe, Stern, Mariana C., Krieger, Janice L., Aparicio, Jose, Hensel, Brooke, Askins, Nissa, Abreu, Andre, Adams, Angela, Agyare, Edward, Ali, Jamel, Allen, John M., Aló, Richard, Baezconde-Garbanati, Lourdes, Brant, Jason, Brown, Clyde P., Buxbaum, Sarah G., Cohen, Pinchas, Cozen, Wendy, Ezenwa, Miriam O., Falzarano, Sara, Fillingim, Roger B., Flores-Rozas, Hernan, Fredenburg, Kristianna M., George, Thomas, Han, Bo, Huang, Yong, Hughes Halbert, Chanita, Kiros, Gebre-Egziabher, Lamango, Nazarius S., Lee, Ji-Hyun, Lyon, Debra E., Mitchell, Duane A., Mochona, Bereket, Nieva, Jorge J., Offringa, Ite A., Okunieff, Paul, Parker, Alexander, Rhie, Suhn K., Richey, Joyce M., Rogers, Sherise C., Salhia, Bodour, Schmittgen, Thomas D., Segal, Richard, Setiawan, Veronica W., Smith, Ukamaka, Su, Li-Ming, Suther, Sandra, Trevino, Jose, Velazquez-Villarreal, Enrique I., Webb, Fern J., Wu, Anna H., Yao, Yingwei, Wilkie, Diana J.

“…Introduction The Florida-California Cancer Research, Education, and Engagement (CaRE2) Health Equity Center is a triad partnership committed to increasing…”
Get full text

Prognosis and Treatment Outcomes of Bone Metastasis in Gallbladder Adenocarcinoma: A SEER-Based Study by Gera, Kriti, Kahramangil, Doga, Fenton, Graeme A, Martir, Daniela, Rodriguez, Diana N, Ijaz, Zohaib, Lin, Rick Y, Rogers, Sherise C, Ramnaraign, Brian H, George, Thomas J, Hong, Young-Rock, Hughes, Steven J, Nassour, Ibrahim, Sahin, Ilyas

“…Gallbladder carcinoma (GBC) is a rare, aggressive malignancy comprising 0.5% of gastrointestinal cancers. It has poor survival outcomes due to its insidious…”
Get full text

A phase II study of neoadjuvant liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in pancreatic adenocarcinoma by Singhal, Ruchi, Rogers, Sherise C, Lee, Ji-Hyun, Ramnaraign, Brian, Sahin, Ilyas, Fabregas, Jesus C, Thomas, Ryan M, Hughes, Steven J, Nassour, Ibrahim, Hitchcock, Kathryn, Russell, Karen, Kayaleh, Omar, Turk, Anita, Zlotecki, Robert, DeRemer, David L, George, Thomas J

“…For patients with localized pancreatic cancer with minimal vascular involvement, optimal survivability requires a multidisciplinary approach of surgical…”
Get full text

Chemotherapy is associated with improved survival in a national cohort of stage IV pancreatic adenosquamous carcinoma by Altshuler, Ellery, Riner, Andrea N, Herremans, Kelly M, George, Thomas J, Rogers, Sherise C, Paniccia, Alessandro, Hughes, Steven J, Fabregas, Jesus C, Nassour, Ibrahim

“…Pancreatic adenosquamous carcinoma (PASC) is a rare cancer that often presents with advanced disease and carries a grim prognosis. PASC is defined by the…”
Get full text

Atezolizumab plus tivozanib for immunologically cold tumor types: the IMMCO-1 trial by Ramnaraign, Brian H, Lee, Ji-Hyun, Ali, Azka, Rogers, Sherise C, Fabregas, Jesus C, Thomas, Ryan M, Allegra, Carmen J, Sahin, Ilyas, DeRemer, David L, George, Thomas J, Chatzkel, Jonathan A

“…Immune checkpoint inhibitor therapy represents a significant advance in cancer care. The interaction between PD-1 and PD-L1 induces immune tolerance and the…”
Get full text

Clinician-patient communication about cancer treatment misinformation: The Misinformation Response Model by Mullis, M. Devyn, Fisher, Carla L., Johnson, Skyler B., Liu, Tianshi, Amin, Tithi B., Rogers, Sherise, DeGruccio, Kennan, Bylund, Carma L.

“…Cancer treatment misinformation (CTM) is pervasive and impacts patient health outcomes. Cancer clinicians play an essential role in addressing CTM. We…”
Get full text

The First Case of HER2+ Invasive Ductal carcinoma Arising From a Breast Hamartoma and Literature Review by Baer, Lea, M.D, Rogers, Sherise Chantell, M.D., M.P.H, Farrelly, Patricia, M.D, Tornos, Carmen, M.D, Sweeney, Keith, M.D

“…Abstract Carcinomas arising from breast hamartomas are exceedingly rare. We present the first reported case of an African-American female presenting with a…”
Get full text

A nurse‐led intervention in patients with newly diagnosed cancer and Type 2 diabetes: A pilot randomized controlled trial feasibility study by Scarton, Lisa, Nelson, Tarah, Jo, Ara, O’Neal, LaToya J., Yao, Yingwei, Huggins, Shavondra, Legaspi, Anatolia B., McClaren, Mariah J., Cabassa, Jake S., Burgos Melendez, Joan M., Munoz‐Pena, Juan M., Markham, Merry J., Murphy, Martina C., Chatzkel, Jonathan A., Rogers, Sherise, George, Thomas J.

“…Background Undiagnosed Type 2 diabetes (T2D) has been associated with advanced stage cancer at diagnosis, higher mortality, and lower long‐term all‐cause…”
Get full text

Effects of Clinical and Tumor Characteristics on Survival in Patients with Hepatocellular Carcinoma with Bone Metastasis by Ozer, Muhammet, Goksu, Suleyman Yasin, Lin, Rick Y, Ayasun, Ruveyda, Kahramangil, Doga, Rogers, Sherise C, Fabregas, Jesus C, Ramnaraign, Brian H, George, Thomas J, Feely, Michael, Cabrera, Roniel, Duarte, Sergio, Zarrinpar, Ali, Sahin, Ilyas

“…Advanced hepatocellular carcinoma (HCC) generally has a dismal prognosis. Bone metastases from HCC are infrequent, with a poorer prognosis. However, the…”
Get full text

Impact of COVID-19 pandemic on pancreatic cancer disparities and outcomes in Florida by Lim, Alexander, Telisnor, Guettchina, Zhang, Zhongyue, Lou, XiangYang, Nassour, Ibrahim, Salloum, Ramzi, Rogers, Sherise C.

“…667 Background: Pancreatic cancer (PDAC) is the third-leading cause of cancer death in the United States. Florida had a high infection rate with several peaks…”
Get full text

Development of novel pyrimidine nucleoside analogs as potential anticancer agents: Synthesis, characterization, and In-vitro evaluation against pancreatic cancer by Frimpong, Esther, Bulusu, Raviteja, Okoro, Joy, Inkoom, Andriana, Ndemazie, Nkafu, Rogers, Sherise, Zhu, Xue, Han, Bo, Agyare, Edward

“…•Chemically modifying existing anticancer drugs enhances cellular uptake, increasing cytotoxic effects.•Modified 5-FU analogs increased BAX and p53 expression…”
Get full text

Influence of clinical and tumor characteristics on survival in patients with hepatocellular carcinoma with bone metastasis by Ozer, Muhammet, Goksu, Suleyman Yasin, Fabregas, Jesus C., Ramnaraign, Brian Hemendra, Rogers, Sherise C., George, Thomas J., Sahin, Ilyas

“…525 Background: Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer, and the incidence of liver cancer is rapidly rising in the…”
Get full text

Clinical validation of Northstar response: A novel methylated ctDNA therapy response monitoring assay in patients with advanced gastrointestinal cancers by Sahin, Ilyas, Kahramangil, Doga, Kim, George P., Rogers, Sherise C., Ramnaraign, Brian Hemendra, Manda, Pravalika, Varga, Matthew Gordon, Palmer, Gary A., Ye, Patrick Peiyong, George, Thomas J.

“…e16000 Background: Circulating tumor DNA (ctDNA) offers a non-invasive method to comprehensively assess tumors. While most assays for therapy response…”
Get full text

A phase Ib/II study of atezolizumab plus tivozanib in pancreatic, gallbladder, and bile duct malignancies by Ramnaraign, Brian Hemendra, Lee, Ji-Hyun, Sahin, Ilyas, Rogers, Sherise C., Thomas, Ryan M., Allegra, Carmen J., DeRemer, David L., George, Thomas J., Chatzkel, Jonathan Alexander

“…TPS715 Background: Checkpoint inhibitor therapy represents a significant advance in cancer care however it is not an effective intervention in the treatment of…”
Get full text